Lumida
/CTS
⌘K
CTS Corp

CTS Corp

CTS
$59.40USD↓-0.13%-0.08 today

MARKET CAP

1.7B

P/E (TTM)

24.6x

FWD P/E

24.0x

DAY RANGE

$57 – $60

52W RANGE

$36
$70

AI Summary

Stalk
TrimMedium

CTS remains in a Stage 4 – Decline with confirmed lower-highs/lower-lows trading beneath declining 9 EMA, 21 EMA, and 50 SMA while oscillators show oversold conditions. Medium-term bias stays bearish, barring bullish participation. Short-term structure lacks clear reversal, suggesting deferred sell execution. Execution should be staged into rallies toward the declining EMAs and 50 SMA resistance zone to align with the dominant downtrend and favor rejection at those levels.

  • ↑Revenue rose 11% YoY to $139M, with diversification at 60%
  • ↑Medical segment surged 28% YoY to $25M, driven by therapy demand
  • ↓Transportation sales fell 7% amid lower global vehicle volumes
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

CTS Corporation (NYSE: CTS) specializes in the design and manufacturing of sensors and electronic components across diversified markets including medical, aerospace, defense, industrial, and transportation. The company is strategically transitioning to enhance growth by focusing on advanced technologies and expanding its product portfolio in response to evolving market needs, particularly driven by trends such as automation and connectivity.

Bull says

  • ↑Revenue rose 11% YoY to $139M, with diversification at 60%
  • ↑Medical segment surged 28% YoY to $25M, driven by therapy demand
  • ↑Generated $17M operating cash flow and returned $10M via buybacks
  • ↑Strong earnings yield and positive momentum support upside potential
  • ↑Exceeds 200-day moving average at $59.29, indicating price strength
  • ↑2026 revenue guidance of $560–580M underpins growth visibility

Bear says

  • ↓Transportation sales fell 7% amid lower global vehicle volumes
  • ↓Ongoing geopolitical uncertainties may dampen demand in key segments
  • ↓Weak profitability factors and low dividend yield limit returns
  • ↓Lack of institutional support raises susceptibility to volatility
  • ↓Full-year guidance of $560–580M faces cost and execution risks
  • ↓Rising tariffs and costs pressure profit margins

Earnings Call · Q4 2025 · Mgmt. Guidance

Updated 04-22-2026neutral

Transcript signals

Bull points

  • Our adjusted gross margin was 39.1%, up 150 basis points compared to the fourth quarter of 2024, and up 20 basis points compared to the third quarter of 2025. The year-over-year improvement in gross margin was driven by operational improvements and the favorable impact of end market mix.
  • Our adjusted gross margin was 38.5% in 2025, up 150 basis points compared to 2024. Primary drivers of the improved gross margin include the favorable impact of end market mix and operational improvements. Foreign currency rates also had a favorable impact of approximately $2 million in 2025. We remain focused on strengthening our gross margin profile by growing our diversified end markets, as well as continued operational improvements.
  • Our adjusted EBITDA margin for the year was 22.8%, an improvement of 40 basis points from 2024.

Bear points

  • SyQuest added $22 million in revenue in 2025, which was lower than expected, mainly due to the timing of government contract awards.
  • Sales to the transportation end market were down 7%, mainly due to the lower sales of commercial vehicle products.
  • The US tax legislation changes had an adverse impact of approximately 3 cents on adjusted earnings per diluted share for 2025.
Read full transcript analysis ›